contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


bulletin-from-extraordinary-general-meeting-of-q-linea-ab-publ

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Q-Linea är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av instrument och förbrukningsartiklar. Produkterna används huvudsakligen vid behandling av infektionssjukdomar och blodförgiftning, och innefattar diagnostik- och analysverktyg, samt grundläggande provhantering. Tekniken baseras på den så kallade ID- samt AST tekniken. Q-Linea grundades 2008 och har huvudkontor i Uppsala.

Q-Linea

The extraordinary general meeting of Q-linea AB (publ) (the “Company”), corp.reg.no 556729-0217, was held on 3 April 2025 in Uppsala, Sweden, at which the shareholders primarily resolved as ...

<div class="mfn-preamble"><p><strong>The extraordinary general meeting of Q-linea AB (publ) (the “Company”), corp.reg.no 556729-0217, was held on 3 April 2025 in Uppsala, Sweden, at which the shareholders primarily resolved as follows. All resolutions were passed with the required majority.</strong></p></div><div class="mfn-body"><p>The general meeting was held at Advokatfirman Lindahl’s premises in Uppsala. For more detailed information on the content of the resolutions, please see the complete notice of the extraordinary general meeting that is available on the Company’s website, www.qlinea.com. Minutes from the extraordinary general meeting will be provided on the mentioned website within two weeks from the day of the meeting.</p><p><strong class="mfn-heading-1">Amendments to the articles of association</strong></p><p>The general meeting resolved, in accordance with the board of directors' proposal, to amend the articles of association regarding the limits for the share capital in order to implement a reduction of the share capital in the Company.</p><p><strong class="mfn-heading-1">Reduction of the share capital</strong></p><p>The general meeting resolved to reduce the Company's share capital by SEK 177,931,523.84 to be allocated to unrestricted equity. Consequently, the share capital will be reduced from SEK 222,414,404.80 to SEK 44,482,880.96. As a result, the quota value of the Company’s shares will reduce from SEK 0.05 per share to SEK 0.01 per share.<br>The reduction is desirable in view of the upcoming exercise of warrants of series TO1 to ensure that the discount of 30 percent against the volume-weighted average price can be applied (however, according to Euroclear Sweden AB's system, it is technically not possible to have an exercise price below one (1) Swedish öre). An additional reason for the reduction is to achieve a more appropriate share capital for the Company, i.e., to establish a better balance between unrestricted and restricted equity.</p></div><div class="mfn-footer mfn-contacts mfn-828219978778"><p><strong class="mfn-heading-1">For more information, please contact:</strong></p><hr><p>Stuart Gander, President &amp; CEO, Q-linea <br><a rel="noopener" href="mailto:stuart.gander@qlinea.com">Stuart.Gander@qlinea.com</a><br>+1 857 409 7463</p><p>Christer Samuelsson, CFO /IR, Q-linea AB<br><a rel="noopener" href="mailto:Christer.Samuelsson@qlinea.com">Christer.Samuelsson@qlinea.com</a><br>+46 (0) 70-600 15 20<br></p></div><div class="mfn-footer mfn-about mfn-2048cb62925b"><p><strong class="mfn-heading-1">About Q-linea</strong></p><hr><p>Q-linea’s rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.<br>Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.<br>ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/efa3f275-417e-4ac9-934f-8648bf99372b/bulletin-from-extraordinary-general-meeting-of-q-linea-ab-publ.pdf" class="mfn-generated mfn-primary">BULLETIN FROM Extraordinary GENERAL MEETING OF Q-LINEA AB (PUBL)</a></p></div>